Search Results: Treatment + Endometrial Cancer (7 results)
Effectiveness of Lymph Node Mapping to Reduce the Risk of Swelling in the Legs in Patients with Stage I Endometrial Cancer
https://www.facingourrisk.org/research-clinical-trials/study/310/effectiveness-of-lymph-node-mapping-to-reduce-the-risk-of-swelling-in-the-legs-in-patients-with-stage-i-endometrial-cancer
Treatment
People with stage I endometrial cancer who are having a hysterectomy
This study compares the effect of sentinel lymph node mapping to standard lymph node dissection in reducing the risk of swelling in the legs (lymphedema) in patients undergoing a hysterectomy for stage I endometrial cancer.
Study of a New Treatment Called ONM-501 Alone and in Combination with Cemiplimab in People with Triple Negative Breast Cancer, Advanced Solid Tumors and Lymphomas
https://www.facingourrisk.org/research-clinical-trials/study/311/study-of-a-new-treatment-called-onm-501-alone-and-in-combination-with-cemiplimab-in-people-with-triple-negative-breast-cancer-advanced-solid-tumors-and-lymphomas
Treatment
Study of a new drug called ONM-501 for people with triple negative breast cancer, advanced solid tumors or lymphomas
Study of a new drug called ONM-501 for people with triple negative breast cancer, advanced solid tumors or lymphomas
Study of a New Immunotherapy Treatment Called NC410 in People with Different Types of Advanced or Metastatic Cancers
https://www.facingourrisk.org/research-clinical-trials/study/251/study-of-an-immunotherapy-treatment-in-individuals-with-advanced-or-metastatic-solid-tumors
Treatment
People with advanced or metastatic colorectal, endometrial, ovarian, stomach, esophageal or other cancers
This study will test the safety and effectiveness of using a new immunotherapy drug called NC410 to treat people with different types of metastatic or advanced cancers that cannot be removed by surgery. The study is open to people with colorectal, endometrial, ovarian, stomach, esophageal, head and neck and other cancers that:
- have a tumor marker known as microsatellite stable (MSS), OR
- have been treated with and no longer respond to treatment with immunotherapy drugs known as immune checkpoint inhibitors.
A Study of Targeted Therapies for Patients With Recurrent Endometrial Cancer
https://www.facingourrisk.org/research-clinical-trials/study/245/a-study-of-different-targeted-therapies-for-patients-with-recurrent-or-persistent-endometrial-cancer
Treatment
This study is for people with recurrent endometrial cancer
This study is to test the safety and effectiveness of different kinds of targeted therapy with or without atezolizumab (or Tecentriq) in individuals with recurrent or persistent endometrial cancer. Participants will be placed into study groups based on their tumor.
Testing an Immunotherapy, Pembrolizumab, in Patients With Advanced Solid Tumors
https://www.facingourrisk.org/research-clinical-trials/study/234/testing-an-immunotherapy-in-patients-with-advanced-solid-tumors
Treatment
Treatment study for people with advanced cancers
This study is looking at the effectiveness of an immunotherapy, pembrolizumab, in treating people who have been diagnosed with advanced solid tumors that have progressed on standard-of-care therapy.
TAPUR Study: Testing FDA Approved Drugs Targeting Tumor Biomarkers in People with Advanced Stage Cancer
https://www.facingourrisk.org/research-clinical-trials/study/262/tapur-study-testing-fda-approved-drugs-targeting-tumor-gene-abnormalities-in-people-with-advanced-stage-cancer
Treatment
Cancer treatment study for people with advanced solid tumors
The TAPUR Study aims to describe the safety and efficacy of Food and Drug Administration (FDA)-approved, targeted anticancer drugs prescribed for treatment of patients with advanced cancer that has a potentially actionable genomic alteration.
Nivolumab and Relatlimab in Advanced Mismatch Repair Deficient (dMMR/MSI-High) Cancers Resistant to Prior PD-L1 Inhibitor
https://www.facingourrisk.org/research-clinical-trials/study/151/nivolumab-and-relatlimab-in-advanced-msi-h-cancers-resistant-to-prior-pd-l1-inhibitor
Treatment
Solid tumors that are MSI-High and resistant to prior immunotherapy
The purpose of this study is to evaluate the safety, effectiveness, and tolerability of using the immunotherapy drugs nivolumab and relatlimab in patients with microsatellite instability high (MSI-H) solid tumors resistant to prior PD-L1 therapy.
Both nivolumab and relatlimab are a type of immunotherapy known as immune checkpoint inhibitors. Immune checkpoint inhibitors are drugs that prevent cancer cells from switching off immune cells. This allows the immune system to find, unmask and destroy cancer cells.
Additional Results on Clinicaltrials.gov Treatment + Endometrial Cancer
107 results
Study of REGN4018 Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
NCT ID: NCT03564340 (https://clinicaltrials.gov/study/NCT03564340)
Choosing Ovarian Preservation or Removal Before Surgery for Endometrial Cancer
NCT ID: NCT04569773 (https://clinicaltrials.gov/study/NCT04569773)
Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax
NCT ID: NCT05092373 (https://clinicaltrials.gov/study/NCT05092373)
A Trial to Find Out How Safe REGN5668 is and How Well it Works When Given With Either Cemiplimab or REGN4018
NCT ID: NCT04590326 (https://clinicaltrials.gov/study/NCT04590326)
Testing the Addition of Trastuzumab or Trastuzumab/Pertuzumab to the Usual Chemotherapy for HER2 Positive Endometrial Cancer
NCT ID: NCT05256225 (https://clinicaltrials.gov/study/NCT05256225)
Alternate Day Fasting After Surgery for Patients Undergoing Chemotherapy
NCT ID: NCT05990426 (https://clinicaltrials.gov/study/NCT05990426)
A Study of GV20-0251 Monotherapy and GV20-0251 in Combination with Pembrolizumab in Participants with Solid Tumor Malignancies
NCT ID: NCT05669430 (https://clinicaltrials.gov/study/NCT05669430)
A Study of LY2880070 in Participants With Advanced or Metastatic Cancer
NCT ID: NCT02632448 (https://clinicaltrials.gov/study/NCT02632448)
Megestrol Acetate Compared With Megestrol Acetate and Metformin to Prevent Endometrial Cancer
NCT ID: NCT04576104 (https://clinicaltrials.gov/study/NCT04576104)
Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)
NCT ID: NCT02628067 (https://clinicaltrials.gov/study/NCT02628067)
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
NCT ID: NCT05059444 (https://clinicaltrials.gov/study/NCT05059444)
An Enhanced Vaginal Dilator to Reduce Radiation-Induced Vaginal Stenosis
NCT ID: NCT03876860 (https://clinicaltrials.gov/study/NCT03876860)
A Study of CPI-0209 in Patients With Advanced Solid Tumors and Lymphomas
NCT ID: NCT04104776 (https://clinicaltrials.gov/study/NCT04104776)
Genetic Testing in African Americans
NCT ID: NCT05591131 (https://clinicaltrials.gov/study/NCT05591131)
Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer
NCT ID: NCT05797831 (https://clinicaltrials.gov/study/NCT05797831)
A Phase I/IIa Study of AZD8205 Given Alone or in Combination With Anticancer Drugs, in Participants With Advanced or Metastatic Solid Malignancies
NCT ID: NCT05123482 (https://clinicaltrials.gov/study/NCT05123482)
Pembrolizumab, Lenvatinib and IL-15 Superagonist N-803 in Combination With HER2 Targeting Autologous Dendritic Cell (AdHER2DC) Vaccine in Participants With Advanced or Metastatic Endometrial Cancer
NCT ID: NCT06253494 (https://clinicaltrials.gov/study/NCT06253494)
Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the PI3K/mTOR Inhibitor Gedatolisib (PF-05212384) for Patients With Advanced Squamous Cell Lung, Pancreatic, Head & Neck and Other Solid Tumors
NCT ID: NCT03065062 (https://clinicaltrials.gov/study/NCT03065062)
Phase I Trial Testing the Safety and Tolerability of Chemoradiation Followed by Chemotherapy + Dostarlimab for Stage IIIC, Node Positive, Endometrial Cancer
NCT ID: NCT05819892 (https://clinicaltrials.gov/study/NCT05819892)
Mindfulness in Endometrial and Cervical Cancer
NCT ID: NCT04512144 (https://clinicaltrials.gov/study/NCT04512144)
Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors
NCT ID: NCT03682289 (https://clinicaltrials.gov/study/NCT03682289)
Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors
NCT ID: NCT05887492 (https://clinicaltrials.gov/study/NCT05887492)
A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors
NCT ID: NCT05150691 (https://clinicaltrials.gov/study/NCT05150691)
Bariatric Education for Women With Obesity and Endometrial Cancer
NCT ID: NCT05396794 (https://clinicaltrials.gov/study/NCT05396794)
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants with Advanced Solid Tumors
NCT ID: NCT05592626 (https://clinicaltrials.gov/study/NCT05592626)
ACE1702 in Subjects With Advanced or Metastatic HER2-expressing Solid Tumors
NCT ID: NCT04319757 (https://clinicaltrials.gov/study/NCT04319757)
A Tissue Collection Study in Patients Who Respond to Immune Checkpoint Inhibitors to Identify Targets of Tumor-Reactive T Cells.
NCT ID: NCT05230186 (https://clinicaltrials.gov/study/NCT05230186)
First-in-Human Study of STX-478 as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
NCT ID: NCT05768139 (https://clinicaltrials.gov/study/NCT05768139)
Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer
NCT ID: NCT05051722 (https://clinicaltrials.gov/study/NCT05051722)
Bone Marrow Sparing Image-Guided Radiation Therapy (RT) Incorporating Novel Use of GCSF and FDG-PET Imaging
NCT ID: NCT04514692 (https://clinicaltrials.gov/study/NCT04514692)
A Beta-only IL-2 ImmunoTherapY Study
NCT ID: NCT05086692 (https://clinicaltrials.gov/study/NCT05086692)
Bevacizumab and/or Niraparib in Patients With Recurrent Endometrial and/or Ovarian Cancer With ARID1A Mutation
NCT ID: NCT05523440 (https://clinicaltrials.gov/study/NCT05523440)
A Study of SGN-B7H4V in Advanced Solid Tumors
NCT ID: NCT05194072 (https://clinicaltrials.gov/study/NCT05194072)
Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer
NCT ID: NCT05997017 (https://clinicaltrials.gov/study/NCT05997017)
A Study of ACR-368 in Ovarian Carcinoma, Endometrial Adenocarcinoma, and Urothelial Carcinoma
NCT ID: NCT05548296 (https://clinicaltrials.gov/study/NCT05548296)
Impact of Sentinel Lymph Node Mapping on Patient Reported Lower Extremity Limb Dysfunction in Stage I Endometrial Cancer
NCT ID: NCT05646316 (https://clinicaltrials.gov/study/NCT05646316)
Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors
NCT ID: NCT02611024 (https://clinicaltrials.gov/study/NCT02611024)
Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005)
NCT ID: NCT06132958 (https://clinicaltrials.gov/study/NCT06132958)
(VELA) Study of BLU-222 in Advanced Solid Tumors
NCT ID: NCT05252416 (https://clinicaltrials.gov/study/NCT05252416)
Pilot Window of Opportunity Trial (POET)
NCT ID: NCT06129604 (https://clinicaltrials.gov/study/NCT06129604)
Telemedicine Use in Preoperative Counseling for Endometrial Cancer Survivors
NCT ID: NCT05712668 (https://clinicaltrials.gov/study/NCT05712668)
A Study of LY4170156 in Participants With Selected Advanced Solid Tumors
NCT ID: NCT06400472 (https://clinicaltrials.gov/study/NCT06400472)
Observational Study of Women With Endometrial Cancer Who Receive the Standard Treatment for Their Disease
NCT ID: NCT04291612 (https://clinicaltrials.gov/study/NCT04291612)
Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma
NCT ID: NCT05112601 (https://clinicaltrials.gov/study/NCT05112601)
Testing the Combination of APG-1252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial Cancers
NCT ID: NCT05691504 (https://clinicaltrials.gov/study/NCT05691504)
IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors
NCT ID: NCT05039801 (https://clinicaltrials.gov/study/NCT05039801)
Phase 1 Clinical Trial of Lenvatinib, Pembrolizumab and Hypofractionated Pelvic Radiation Therapy for pMMR Recurrent/Unresectable Endometrial Carcinoma
NCT ID: NCT05603910 (https://clinicaltrials.gov/study/NCT05603910)
A Study of Short-Course Radiation Therapy With Chemotherapy in People With Endometrial Cancer
NCT ID: NCT05691010 (https://clinicaltrials.gov/study/NCT05691010)
Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors
NCT ID: NCT05269381 (https://clinicaltrials.gov/study/NCT05269381)
Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies
NCT ID: NCT04644068 (https://clinicaltrials.gov/study/NCT04644068)
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
NCT ID: NCT04585750 (https://clinicaltrials.gov/study/NCT04585750)
Prediction of Recurrence Among Low Risk Endometrial Cancer Patients
NCT ID: NCT04604613 (https://clinicaltrials.gov/study/NCT04604613)
Tailoring Therapy in Post-surgical Patients With Low-risk Endometrial Cancer
NCT ID: NCT06388018 (https://clinicaltrials.gov/study/NCT06388018)
Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Immunotherapy (ASCENT-GYN-01/GOG-3104/ENGOT-en26)
NCT ID: NCT06486441 (https://clinicaltrials.gov/study/NCT06486441)
Study of Favezelimab Coformulated With Pembrolizumab (MK-4280A) in Participants With Selected Solid Tumors (MK-4280A-010)
NCT ID: NCT06036836 (https://clinicaltrials.gov/study/NCT06036836)
Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER
NCT ID: NCT05640999 (https://clinicaltrials.gov/study/NCT05640999)
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
NCT ID: NCT06270706 (https://clinicaltrials.gov/study/NCT06270706)
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
NCT ID: NCT04851119 (https://clinicaltrials.gov/study/NCT04851119)
Talazoparib and Radiation Therapy in Treating Patients With Locally Recurrent Gynecologic Cancers
NCT ID: NCT03968406 (https://clinicaltrials.gov/study/NCT03968406)
TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers
NCT ID: NCT04485013 (https://clinicaltrials.gov/study/NCT04485013)
Radiation and TSR-042 (Dostarlimab) in People With Endometrial Cancer After They Receive Surgery
NCT ID: NCT04774419 (https://clinicaltrials.gov/study/NCT04774419)
Concurrent Laparoscopic Hysterectomy and Weight Loss Surgery in Obese Patients With Endometrial Carcinoma or Endometrial Intraepithelial Neoplasia
NCT ID: NCT04839614 (https://clinicaltrials.gov/study/NCT04839614)
A Phase II Study of Futibatinib and Pembrolizumab in Metastatic Microsatellite Stable Endometrial Carcinoma
NCT ID: NCT05036681 (https://clinicaltrials.gov/study/NCT05036681)
Study of the CHK1 Inhibitor BBI-355, an EcDNA-directed Therapy (ecDTx), in Subjects with Tumors with Oncogene Amplifications
NCT ID: NCT05827614 (https://clinicaltrials.gov/study/NCT05827614)
Specimen and Data Study for Ovarian Cancer Early Detection and Prevention
NCT ID: NCT00005095 (https://clinicaltrials.gov/study/NCT00005095)
Hypofractionated External Beam Radiotherapy With Adaptive Planning for Endometrial and Cervical Cancers
NCT ID: NCT06538337 (https://clinicaltrials.gov/study/NCT06538337)
A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer
NCT ID: NCT04486352 (https://clinicaltrials.gov/study/NCT04486352)
Adjuvant Hypofractionated Whole Pelvis Radiation Therapy in Endometrial Cancer
NCT ID: NCT04458402 (https://clinicaltrials.gov/study/NCT04458402)
Abemaciclib for the Treatment of Recurrent Ovarian or Endometrial Cancer
NCT ID: NCT04469764 (https://clinicaltrials.gov/study/NCT04469764)
A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors
NCT ID: NCT06257264 (https://clinicaltrials.gov/study/NCT06257264)
A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants With Advanced Unresectable or Metastatic Solid Tumors
NCT ID: NCT05572684 (https://clinicaltrials.gov/study/NCT05572684)
Trial of Maintenance With Niraparib- Uterine Serous Carcinoma
NCT ID: NCT04080284 (https://clinicaltrials.gov/study/NCT04080284)
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer
NCT ID: NCT01174121 (https://clinicaltrials.gov/study/NCT01174121)
Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer
NCT ID: NCT05950464 (https://clinicaltrials.gov/study/NCT05950464)
Cabozantinib and Dostarlimab in Recurrent Gynecologic Carcinosarcoma
NCT ID: NCT05559879 (https://clinicaltrials.gov/study/NCT05559879)
Avelumab and M1774 in ARID1A-mutated Endometrial Cancer (Prior IO)
NCT ID: NCT06518564 (https://clinicaltrials.gov/study/NCT06518564)
HPV Vaccine, Imiquimod, and Metformin Combination Trial
NCT ID: NCT06686043 (https://clinicaltrials.gov/study/NCT06686043)
Determine the Utility of Liquid Biopsies and Tumor Molecular Profiling in Predicting Recurrence in High-Risk Endometrial Cancers
NCT ID: NCT05049538 (https://clinicaltrials.gov/study/NCT05049538)
A Study of PARG Inhibitor IDE161 in Participants with Advanced Solid Tumors
NCT ID: NCT05787587 (https://clinicaltrials.gov/study/NCT05787587)
A Study of Alpelisib and Fulvestrant to Treat Endometrial Cancer
NCT ID: NCT05154487 (https://clinicaltrials.gov/study/NCT05154487)
Exercise as a Preventive Agent to Combat Immobility in Patients With Ovarian or Endometrial Cancers Receiving Chemotherapy
NCT ID: NCT04997096 (https://clinicaltrials.gov/study/NCT04997096)
The UPPROACH (Upfront Intensity Modulated Proton Beam Therapy) Approach
NCT ID: NCT04527900 (https://clinicaltrials.gov/study/NCT04527900)
ADP-A2M4CD8 as Monotherapy or in Combination With Either Nivolumab or Pembrolizumab in HLA-A2+ Subjects With MAGE-A4 Positive Tumors (SURPASS)
NCT ID: NCT04044859 (https://clinicaltrials.gov/study/NCT04044859)
Uterine Manipulation During Minimally Invasive Surgery for Early Stage Endometrial Cancer
NCT ID: NCT04586959 (https://clinicaltrials.gov/study/NCT04586959)
A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
NCT ID: NCT06607185 (https://clinicaltrials.gov/study/NCT06607185)
A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRĪ±)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
NCT ID: NCT04300556 (https://clinicaltrials.gov/study/NCT04300556)
Frontline Immunotherapy Combined With Radiation and Chemotherapy in High Risk Endometrial Cancer
NCT ID: NCT03932409 (https://clinicaltrials.gov/study/NCT03932409)
Fasting Mimicking Diet for Reducing Immune Related Adverse Events for Cancer Patients on Immune Checkpoint Inhibitors, FMD-ICI Trial
NCT ID: NCT06438588 (https://clinicaltrials.gov/study/NCT06438588)
Vaginal Cuff Brachytherapy Fractionation Study
NCT ID: NCT03785288 (https://clinicaltrials.gov/study/NCT03785288)
PROton Therapy for Post Surgical Treatment of GYNecologic Cancer
NCT ID: NCT05758688 (https://clinicaltrials.gov/study/NCT05758688)
ONC201 and Atezolizumab in Obesity-Driven Endometrial Cancer
NCT ID: NCT05542407 (https://clinicaltrials.gov/study/NCT05542407)
Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial
NCT ID: NCT05554328 (https://clinicaltrials.gov/study/NCT05554328)
Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
NCT ID: NCT05489211 (https://clinicaltrials.gov/study/NCT05489211)
Discovering New Targets for Colorectal and Endometrial Cancer Risk Reduction
NCT ID: NCT06096688 (https://clinicaltrials.gov/study/NCT06096688)
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
NCT ID: NCT06172478 (https://clinicaltrials.gov/study/NCT06172478)
Comparison of Proton or Intensity Modulated Radiation Therapy After Surgery for Endometrial or Cervical Cancer
NCT ID: NCT04567771 (https://clinicaltrials.gov/study/NCT04567771)
Short Course Vaginal Cuff Brachytherapy in Treating Participants With Stage I-II Endometrial Cancer
NCT ID: NCT03422198 (https://clinicaltrials.gov/study/NCT03422198)
Study of Narazaciclib (ON 123300) Plus Letrozole in Endometrial Cancer and Other Gynecologic Malignancies
NCT ID: NCT05705505 (https://clinicaltrials.gov/study/NCT05705505)
A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor
NCT ID: NCT04008797 (https://clinicaltrials.gov/study/NCT04008797)
Testing the Addition of the AKT Inhibitor, Ipatasertib, to Treatment With the Hormonal Agent Megestrol Acetate for Recurrent or Metastatic Endometrial Cancers
NCT ID: NCT05538897 (https://clinicaltrials.gov/study/NCT05538897)
Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Patients With Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial
NCT ID: NCT04704661 (https://clinicaltrials.gov/study/NCT04704661)
ALPINE: Maintenance Letrozole/Abemaciclib Vs Pembrolizumab
NCT ID: NCT06366347 (https://clinicaltrials.gov/study/NCT06366347)
Study of Pelvic Hypofractionated Radiotherapy in Endometrial Cancer
NCT ID: NCT04683653 (https://clinicaltrials.gov/study/NCT04683653)
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
NCT ID: NCT05564377 (https://clinicaltrials.gov/study/NCT05564377)
Use of an Intrauterine Manipulator and Its Correlation With Positive Peritoneal Cytology in Early Stage Endometrial Cancers
NCT ID: NCT04570553 (https://clinicaltrials.gov/study/NCT04570553)
First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors
NCT ID: NCT05277051 (https://clinicaltrials.gov/study/NCT05277051)
Phase 2 Study Evaluating the Efficacy of the Combination of DKN-01 (DKK1 Inhibitor, Leap Therapeutics) and Pembrolizumab in the Treatment of Advanced or Recurrent Endometrial Cancer
NCT ID: NCT05761951 (https://clinicaltrials.gov/study/NCT05761951)
About FORCE
FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.